There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly, after tirzepatide's late-stage cardio win, plots regulatory filings this year As for Alzheimer’s and other neurocognitive disorders, the research showed that use of the new diabetes ...

The study included people taking different types drugs in this category—semaglutide (Wegovy and Ozempic), and tirzepatide (Mounjaro and Zepbound). While tirzepatide targets two hormones—GLP-1 ...